A Case of Basal Cell Carcinoma Which Responded to Imiquimod

Kim, Ji Eun; Cho, Wan Ik; Seo, Seong Jun; Hong, Chang Kwun; Song, Kye Yong

Abstract

Basal cell carcinoma (BCC) in the skin is the most common malignancy worldwide. Surgery is still the golden standard treatment for BCCs, but it may be intensive and sometimes excessively destructive. Imiquimod is a member of novel class of immune response modifiers which stimulate or enhance both the innate immune system and cell-mediated immune response and approved by FDA for treating anogenital wart. A 73-year-old male patient was presented with 8x10cm sized erythematous scaly, peripheral ridging patch with central black colored crust on the back. Histopathological finding showed masses of various shapes and sizes composed of basalioma cells. He refused surgery treatment, so we tried 5% imiquimod cream (AldaraTM, 3M) topically three times weekly for the duration of 7 months. Although lesions had incompletely resolved, clinically and histopathologically improvement was observed. Herein we report a case of basal cell carcinoma which responded to imiquimod.